Skip to main content
Key Specialties
Anesthesiology Cardiology Dermatology Diabetology Endocrinology Gastroenterology General Medicine Geriatrics Hematology Infectious Diseases Internal Medicine Nephrology Neurology Obstetrics and Gynecology Oncology Pediatrics Psychiatry Radiology Respiratory Medicine Rheumatology Surgery Urology
Congress Coverage
2024 ERS Congress 2024 EASD Congress 2024 ESC Congress 2024 EAN Congress 2024 ASCO Annual Meeting 2024 ACC Congress
Clinical Collections
Advances in Alzheimer’s

ERS Congress 2024

Keep up to date on the latest news from the annual European Respiratory Society conference.
ADVANCED SEARCH
Log in
Top
BMC Cardiovascular Disorders
Published in:

Open Access 12-08-2024 | Heart Failure | Case Report

Case report: heart failure related to intravitreal injection of anti-VEGF

Authors: Yuying Sui, Yong Zhao, Nannan Zhou, Haihui Sun, Yuanyuan Sun, Junni Liu, Zunzhe Wang, Jianchun Wang

Published in: BMC Cardiovascular Disorders | Issue 1/2024

Login to get access

Abstract

Background

Intravitreal injection of anti-vascular endothelial growth factor is considered the first-line treatment for polypoidal choroidal vasculopathy. It has potential risks for circulatory system, which should be particularly carefully evaluated in older patients. In this case study, we aim to discuss the potential impact of this treatment regimen on cardiac health.

Case presentation

This case report describes an elderly patient with no prior history of heart disease who exhibited unexpected heart enlargement and dysfunction. Throughout the patient’s hospital stay, various potential causes were investigated, leading to the hypothesis that a 10-year history of intravitreal injections of anti-vascular endothelial growth factor could be related to the observed clinical manifestations. The patient was advised to discontinue this treatment, and after a 2-month follow-up period, there was a gradual improvement in the patient’s cardiac structure and function.

Conclusion

This manuscript highlights the importance of conducting cardiac examinations before and after anti-vascular endothelial growth factor treatment, especially for individuals at risk of heart diseases like the elderly. It emphasizes the need to carefully weigh the benefits and risks of treatment regimens to ensure optimal therapeutic outcomes.
Literature
1.
ElSheikh RH, Chauhan MZ, Sallam AB. Current and novel therapeutic approaches for treatment of Neovascular Age-Related Macular Degeneration. Biomolecules. 2022;12(11).
2.
Cheung C, Arnold JJ, Holz FG, et al. Myopic Choroidal neovascularization: review, Guidance, and Consensus Statement on Management. Ophthalmology. 2017;124(11):1690–711.CrossRefPubMed
3.
Hanna RM, Ahdoot RS, Kim MS, et al. Intravitreal vascular endothelial growth factors hypertension, proteinuria, and renal injury: a concise review. Curr Opin Nephrol Hypertens. 2022;31(1):47–56.CrossRefPubMed
4.
Yoshimoto M, Takeda N, Yoshimoto T, Matsumoto S. Hypertensive cerebral hemorrhage with undetectable plasma vascular endothelial growth factor levels in a patient receiving intravitreal injection of aflibercept for bilateral diabetic macular edema: a case report. J Med Case Rep. 2021;15(1):403.CrossRefPubMedPubMedCentral
5.
Yancy CW, Jessup M, Bozkurt B, et al. 2017 ACC/AHA/HFSA focused update of the 2013 ACCF/AHA Guideline for the management of Heart failure: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice guidelines and the Heart Failure Society of America. Circulation. 2017;136(6):e137–61.CrossRefPubMed
6.
Huang CY, Lien R, Wang NK, et al. Changes in systemic vascular endothelial growth factor levels after intravitreal injection of aflibercept in infants with retinopathy of prematurity. Graefes Arch Clin Exp Ophthalmol. 2018;256(3):479–87.CrossRefPubMed
7.
Rogers CA, Scott LJ, Reeves BC, et al. Serum vascular endothelial growth factor levels in the IVAN Trial; relationships with Drug, Dosing, and systemic serious adverse events. Ophthalmol Retina. 2018;2(2):118–27.CrossRefPubMedPubMedCentral
8.
Woo SJ, Veith M, Hamouz J, et al. Efficacy and safety of a proposed Ranibizumab Biosimilar Product vs a reference Ranibizumab product for patients with Neovascular Age-Related Macular Degeneration: a Randomized Clinical Trial. JAMA Ophthalmol. 2021;139(1):68–76.CrossRefPubMed
9.
Zehetner C, Kralinger MT, Modi YS, et al. Systemic levels of vascular endothelial growth factor before and after intravitreal injection of aflibercept or ranibizumab in patients with age-related macular degeneration: a randomised, prospective trial. Acta Ophthalmol. 2015;93(2):e154–9.CrossRefPubMed
10.
Bhisitkul RB, Desai SJ, Boyer DS, Sadda SR, Zhang K. Fellow Eye comparisons for 7-Year outcomes in Ranibizumab-treated AMD subjects from Anchor, Marina, and Horizon (SEVEN-UP study). Ophthalmology. 2016;123(6):1269–77.CrossRefPubMed
11.
Brynskov T, Munch IC, Larsen TM, Erngaard L, Sorensen TL. Real-world 10-year experiences with intravitreal treatment with ranibizumab and aflibercept for neovascular age-related macular degeneration. Acta Ophthalmol. 2020;98(2):132–8.CrossRefPubMed
12.
Maharaj AS, Walshe TE, Saint-Geniez M, et al. VEGF and TGF-beta are required for the maintenance of the choroid plexus and ependyma. J Exp Med. 2008;205(2):491–501.CrossRefPubMedPubMedCentral
13.
Mack CA, Patel SR, Schwarz EA, et al. Biologic bypass with the use of adenovirus-mediated gene transfer of the complementary deoxyribonucleic acid for vascular endothelial growth factor 121 improves myocardial perfusion and function in the ischemic porcine heart. J Thorac Cardiovasc Surg. 1998;115(1):168–76. discussion 176-7.CrossRefPubMedPubMedCentral
14.
Zhang Y, Yang Y, Hosaka K, et al. Endocrine vasculatures are preferable targets of an antitumor ineffective low dose of anti-VEGF therapy. Proc Natl Acad Sci U S A. 2016;113(15):4158–63.CrossRefPubMedPubMedCentral
15.
Yokomori H, Oda M, Yoshimura K, et al. Vascular endothelial growth factor increases fenestral permeability in hepatic sinusoidal endothelial cells. Liver Int. 2003;23(6):467–75.CrossRefPubMed
16.
17.
Parab S, Card OA, Chen Q et al. Local angiogenic interplay of Vegfc/d and Vegfa controls brain region-specific emergence of fenestrated capillaries. Elife. 2023;12.
18.
Rhee S, Chung JI, King DA, et al. Endothelial deletion of Ino80 disrupts coronary angiogenesis and causes congenital heart disease. Nat Commun. 2018;9(1):368.CrossRefPubMedPubMedCentral
19.
Kamba T, Tam BY, Hashizume H, et al. VEGF-dependent plasticity of fenestrated capillaries in the normal adult microvasculature. Am J Physiol Heart Circ Physiol. 2006;290(2):H560–76.CrossRefPubMed
20.
Zhong P, He M, Yu H, et al. A Meta-Analysis of Cardiovascular events Associated with Intravitreal Anti-VEGF treatment in patients with retinal vein occlusion. Curr Eye Res. 2020;45(5):615–22.CrossRefPubMed
21.
Lees JS, Dobbin S, Elyan B et al. A systematic review and meta-analysis of the effect of intravitreal VEGF inhibitors on cardiorenal outcomes. Nephrol Dial Transpl. 2022.
22.
Yin X, He T, Yang S, Cui H, Jiang W. Efficacy and safety of Antivascular endothelial growth factor (Anti-VEGF) in treating Neovascular Age-Related Macular Degeneration (AMD): a systematic review and Meta-analysis. J Immunol Res. 2022;2022:6004047.CrossRefPubMedPubMedCentral
23.
Zhao XY, Meng LH, Liu SZ, Chen YX. Efficacy and safety of different agents, dosages and strategies of anti-vascular endothelial growth factor treatment for neovascular age-related macular degeneration: a network meta-analysis of randomized controlled trials. Acta Ophthalmol. 2021;99(7):e1041–50.CrossRefPubMed
24.
Ngo NN, Thulliez M, Paintaud G, et al. Cardiovascular adverse events with Intravitreal Anti-vascular endothelial growth factor drugs: a systematic review and Meta-analysis of Randomized clinical trials. JAMA Ophthalmol. 2021;139(6):1–11.
25.
Damluji AA, Chung SE, Xue QL, et al. Frailty and cardiovascular outcomes in the National Health and Aging trends Study. Eur Heart J. 2021;42(37):3856–65.CrossRefPubMedPubMedCentral
Metadata
Title
Case report: heart failure related to intravitreal injection of anti-VEGF
Authors
Yuying Sui
Yong Zhao
Nannan Zhou
Haihui Sun
Yuanyuan Sun
Junni Liu
Zunzhe Wang
Jianchun Wang
Publication date
12-08-2024
Publisher
BioMed Central
Published in
BMC Cardiovascular Disorders / Issue 1/2024
Electronic ISSN: 1471-2261
DOI
https://doi.org/10.1186/s12872-024-04095-4

Other articles of this Issue 1/2024

BMC Cardiovascular Disorders 1/2024 Go to the issue

Research

Identification of hub glycolysis-related genes in acute myocardial infarction and their correlation with immune infiltration using bioinformatics analysis

Research

Effect of NLRP3 gene knockdown on pyroptosis and ferroptosis in diabetic cardiomyopathy injury

Case Report

Late coronary artery injury following chemoradiotherapy for thymic carcinoma: a case report

Research

Genetically predicted hypothyroidism, thyroid hormone treatment, and the risk of cardiovascular diseases: a mendelian randomization study

Research

Days alive and out of hospital for adult female and male cardiac surgery patients: a population-based cohort study

Case Report

Zolpidem-triggered atrial fibrillation in a patient with cardiomyopathy: a case report

2024 ESC Congress

Noise pollution dangerous for heart health

Two studies underscore the adverse impact of noise pollution on the risk for and prognosis after myocardial infarction.

Read more

Post-TAVI follow up: deploying virtual assistants

Antihypertensives: more effective at morning or night?

Low Lp(a) levels unlikely to increase the risk of diabetes

» View more highlights on the 2024 ESC Congress hub page

A quick guide to ECGs

Improve your ECG interpretation skills with this comprehensive, rapid, interactive course. Expert advice provides detailed feedback as you work through 50 ECGs covering the most common cardiac presentations to ensure your practice stays up to date. 

PD Dr. Carsten W. Israel
Developed by: Springer Medizin
Start the cases

Keynote webinar | Spotlight on medication adherence

  • Webinar | 27-06-2024 | 18:00 (CEST)

Medication non-adherence is a major barrier to effective healthcare delivery; half of all patients do not follow their doctor’s recommendations or treatment plan.

Our experts explain the fundamentals with a practical discussion of how to manage non-adherence in two common scenarios: hypertension and asthma control.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Watch now
Image Credits